Radar · Life Sciences in Center District
Best Life Sciences Companies in Center District, Israel
The 163 best Life Sciences companies in Center District, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Vayyar.
By Rohit KhannaTrends & Stories
163companies tracked
$1.5Bdisclosed funding
1unicorns
54have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × CENTER DISTRICT
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
75%cloud-native stacks
2024funding peak (by rounds)
1unicorns
2014median founding year
161kcombined LinkedIn audience
40%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Center District
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Vayyar 🦄 Developer of 4D imaging sensors for cancer detection and other devices | $296M | 48 mo ago | Series E | 330 | Raviv Melamed Co-Founder & CEO | Top 5M | — | — |
| 2 | Magenta Medical Venous catheter-based therapy for ADHF 57Patents top 17%Innovation top 21%Funding top 26%Moat top 28% All 10 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 26% Moattop 28% Producttop 31% Markettop 45% Globalbottom 43% Growthbottom 42% Techbottom 34% Newsbottom 21% Patents: 440 patents matched (strict assignee match) · 291 filings since 2022 vs 129 in 2017-21 Innovation: 440 patents (top 6% of patent-holders) · 291 filings since 2022 vs 129 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $183M | 22 mo ago | Series D | 63 | — | — | 440 patents Implantable ventricular assist devices and low-profile blood pump technologies for cardiac support | — |
| 3 | Aspect Imaging Provider of MRI and NMR systems for medical and preclinical imaging solutions | $150M | 110 mo ago | Series C | 87 | Uri Rapport Founder & CEO | Top 10M | 426 patents Advanced MRI hardware and sparse‑sampling reconstruction for brain and susceptibility imaging. | — |
| 4 | BioControl Medical Developer of implantable medical devices for the treatment of heart failure | $70M | 192 mo ago | Series C | 6 | Boaz Lifschitz Co-Founder | — | 34 patents Implantable nerve stimulation devices for gastrointestinal and vagal therapeutic applications | — |
| 5 | SoniVie Developer of denervation catheter for the treatment of pulmonary hypertension | $62M | 41 mo ago | Acquired | 13 | Tomaso Zambelli CEO | Top 10M | 33 patents Medical devices for respiratory/cardiovascular therapy using ultrasound and nerve modulation | — |
| 6 | Emendo Biotherapeutics Provider of re-designed gene-editing tools as drugs for genetic disorders | $61M | 77 mo ago | Acquired | 116 | Shilo Ben Zeev Co-Founder | Top 50M | — | — |
| 7 | BiomX Microbiome therapeutics for diseases associated with microbiome dysbiosis 62Funding top 20%Patents top 34%Growth top 37%Tech top 37% All 9 signals ▾Fundingtop 20% Patentstop 34% Growthtop 37% Techtop 37% Moattop 38% Innovationtop 45% Marketbottom 47% Newsbottom 44% Globalbottom 44% Funding: Raised $56.0M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) Patents: 42 patents matched (strict assignee match) · 24 filings since 2022 vs 18 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $56M | 5 mo ago | Public | 65 | — | Top 10M | 42 patents Therapeutic bacteriophage engineering for targeted bacterial infection and gut microbiome modulation | 2 launchs |
| 8 | BiondVax Developer of a vaccine against influenza virus | $50M | 86 mo ago | Public | — | Amir Reichman Chief Executive Officer | — | — | — |
| 9 | MyHeritage Provider of tools for creating family trees and exploring ancestry | $49M | 162 mo ago | Acquired | 518 | — | Top 10k | — | — |
| 10 | BioProtect Developer of radiation protection technology | $46M | 32 mo ago | Acquired | 1 | Shaul Shohat Co-Founder & CTO | Top 10M | 57 patents Provides inflatable bladder and dilator devices for tissue protection during minimally invasive procedures. | 1 award |
| 11 | Innoventric Developer of transcatheter solutions for patients with heart diseases 40Funding top 31%Moat top 32%Innovation top 41%Patents top 42% All 7 signals ▾Fundingtop 31% Moattop 32% Innovationtop 41% Patentstop 42% Talentbottom 49% Globalbottom 43% Marketbottom 35% Funding: Raised $41.8M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 37 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $42M | 19 mo ago | Series B | 17 | Rafi Benary Founder | — | 37 patents Percutaneous tricuspid valve repair and implantation devices and storage solutions | — |
| 12 | Mapi Pharma Clinical stage pharmaceutical company developing extended release versions of generic drugs. | $40M | 72 mo ago | Series B | 38 | Ehud Marom Chairman & Ceo | Top 10M | 325 patents Patents concentrated in health & consumer products | — |
| 13 | EyeYon Developer of ophthalmic devices for the treatment of corneal edema | $36M | 63 mo ago | Series C | 19 | Nahum Ferera Co-Founder & CEO | Top 50M | — | 1 expansion |
| 14 | Metabomed Developer of targeted therapies to treat cancer | $36M | 78 mo ago | Deadpooled | 7 | — | — | 53 patents ACSS2 enzyme inhibitors for metabolic and oncology drug development | — |
| 15 | Edge Medical Devices Developer of digital radiography display systems | $24M | 203 mo ago | Acqui-Hired | — | — | — | — | — |
| 16 | Regenera Pharma Israeli, clinical stage biopharma developing botanically-derived small molecule therapeutics for optic nerve… | $23M | 101 mo ago | Deadpooled | 6 | Konstantin Adamsky CEO | — | 143 patents Patents concentrated in health & consumer products | — |
| 17 | Kadimastem Stem Cell for the treatment of diabetes mellitus and amyotrophic lateral sclerosis (ALS) | $18M | 55 mo ago | Public | 31 | — | Top 50M | 54 patents Generation and purification of pancreatic endocrine cells for therapeutic applications | 1 partnership |
| 18 | MediWound Developer of enzymatic therapeutic solutions for tissue repair and regeneration 60Talent top 33%Funding top 34%Patents top 36%Global top 39% All 10 signals ▾Talenttop 33% Fundingtop 34% Patentstop 36% Globaltop 39% Innovationtop 43% Newstop 43% Markettop 44% Moattop 44% Techtop 47% Growthbottom 47% Talent: 3 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $18.0M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $18M | 23 mo ago | Public | 83 | Lior Rosenberg Founder & Cmo | Top 10M | 111 patents Topical proteolytic enzyme therapies for skin wounds, psoriasis, and skin cancer treatment. | — |
| 19 | Core Dynamics Organ preservation technologies for the freezing, thawing, and freeze-drying of cells. | $18M | 206 mo ago | Deadpooled | — | Sachi Norman CEO | — | 11 patents Cryogenic preservation and controlled cooling of biological tissues and organs | — |
| 20 | Collplant Developer of recombinant human collagen for regenerative medicine and aesthetics 53Patents top 22%Funding top 26%Product top 26%Tech top 35% All 10 signals ▾Patentstop 22% Fundingtop 26% Producttop 26% Techtop 35% Moattop 35% Innovationtop 43% Newstop 47% Growthbottom 47% Marketbottom 46% Globalbottom 43% Patents: 170 patents matched (strict assignee match) · 41 filings since 2022 vs 46 in 2017-21 Funding: Raised $16.3M across 11 rounds · 11 rounds over 20 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 4 mo ago | Public | 73 | — | Top 10M | 170 patents Collagen-based soft tissue fillers and degradable implants for medical additive manufacturing. | — |
| 21 | 3NT Medical Sinusway device for endoscopy of the nasal cavity & paranasal sinuses | $15M | 91 mo ago | Series A | 17 | Eran Bendory Chief Technology Officer & Co-Founder | — | 46 patents Ear endoscopy and modular cavity access devices for diagnosis and treatment | — |
| 22 | NanoPass Technologies Microneedles-based device for intradermal delivery 37Innovation top 39%Patents top 39%Funding top 42%Moat top 45% All 8 signals ▾Innovationtop 39% Patentstop 39% Fundingtop 42% Moattop 45% Techtop 48% Talentbottom 49% Globalbottom 43% Marketbottom 30% Innovation: 75 patents (top 36% of patent-holders) Patents: 75 patents matched (strict assignee match) · Latest publication 2016 rank vs industry peers · Fliar Intelligence Index 37/100 | $15M | 23 mo ago | Series C | 16 | Daniel Levitats Chief Executive Officer | Top 10M | 75 patents Microneedle-enabled intradermal drug delivery systems and associated manufacturing technologies | 3 launchs · 1 partnership |
| 23 | BELKIN Vision Developer of a laser device for the treatment of glaucoma | $15M | 53 mo ago | Acquired | 20 | — | — | 71 patents Patents concentrated in health & consumer products | — |
| 24 | OCON Medical Developer of nitinol based contraceptive devices for womens health | $15M | 23 mo ago | Series B | 25 | Ilan Baram Founder | Top 10M | 44 patents Intrauterine therapeutic and diagnostic devices for uterine cavity treatment and monitoring. | — |
| 25 | Smart Medical Systems Endoscopes and related devices for GI diseases diagnosis and treatment | $14M | 100 mo ago | Series B | 13 | Gadi Terliuc CEO | Top 50M | 253 patents AI-driven enhanced endoscopic imaging, control, and reprocessing systems for medical diagnostics | — |
| 26 | Versamed Portable life-support ventilators | $13M | 276 mo ago | Acquired | — | — | — | — | — |
| 27 | FEMSelect Developer of minimally invasive uterine prolapse system | $9M | 44 mo ago | Series B | 9 | — | Top 50M | 37 patents Surgical anchoring and tissue repair devices for precise implant placement. | — |
| 28 | Kamari Pharma Developer of therapies for rare dermatologic diseases and itch conditions 22Moat top 32%Patents top 36%Innovation top 42%Funding top 46% All 6 signals ▾Moattop 32% Patentstop 36% Innovationtop 42% Fundingtop 46% Globalbottom 40% Marketbottom 23% Moat: Editorial + unicorn rating 4/10 · IP moat: 28 patents Patents: 28 patents matched (strict assignee match) · 26 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 12 mo ago | Series A | 7 | — | — | 28 patents Topical small‑molecule therapeutics for dermatological disorders and skin symptom relief | — |
| 29 | UroGen Pharma Developer of therapeutics to treat urothelial and specialty cancers | $7M | 34 mo ago | Public | 150 | Ron Bentsur CEO | Top 10M | 80 patents Intravesical drug delivery systems and immunomodulatory therapies for urinary tract cancers | — |
| 30 | VBL Therapeutics Developing gene and small molecule therapies for cancer and inflammation | $7M | 50 mo ago | Public | 7 | — | — | — | — |
| 31 | Quiet Therapeutics Lipid nanoparticles as a mode of delivery to target cancer cells | $6M | 161 mo ago | Series A | 4 | Dan Peer Co-Founder | — | 8 patents Lipidated glycosaminoglycan carriers for nucleic acid delivery | — |
| 32 | Inovytec Critical care devices for emergency conditions | $5M | 112 mo ago | Series A | 31 | — | Top 10M | — | — |
| 33 | CorNeat Vision Developer of nanotechnology-based artificial corneal implants | $4M | 52 mo ago | Series A | 15 | Gilad Litvin Founder & CMO | Top 50M | 69 patents Artificial cornea implants, gingival grafts, and implantable biomedical sensor/polymer devices. | — |
| 34 | BarAlgae Manufacturer and supplier of algae-based animal nutrition products | $3M | 48 mo ago | Seed | — | Maor Sasson Founder & CEO | Top 50M | — | 1 launch |
| 35 | LYDUS MEDICAL Developer of a microvascular suturing device for cardiovascular, transplant, and reconstructive microsurgery. | $3M | 60 mo ago | Seed | 9 | Jessica Weiss CEO | — | 34 patents Surgical anastomosis and knot‑less suturing devices for organ coupling and vascular connections. | — |
| 36 | NeuroDerm Therapies for Parkinson’s disease (PD) and other CNS disorders | $2M | 156 mo ago | Acquired | 55 | Ayelet Altman CEO | Top 10M | 450 patents Formulations and delivery methods for Parkinson’s disease therapeutics. | — |
| 37 | CritiSense Real-time monitoring of patient's metabolic state | $2M | — | Deadpooled | — | Avraham Mayevsky Founder | — | 6 patents Biomedical optical probes for real-time tissue vitality and metabolic emergency monitoring | — |
| 38 | Beta - O2 Developer of an artificial pancreas for releasing insulin | $2M | 136 mo ago | Series A | 17 | Konstantin Bloch Scientific Co-Founder | — | 45 patents Implantable oxygen delivery systems for cell therapy and vascularization | — |
| 39 | miCure Therapeutics Developer of microRNA therapeutics and diagnostics for CNS disorders | $2M | 144 mo ago | Seed | — | Michel Horovitz CEO | — | 8 patents Targeted microRNA therapeutics and neuron-specific oligonucleotide delivery platforms | — |
| 40 | PulmOne Portable medical device for lung function testing | $2M | 107 mo ago | Seed | 41 | Avi Lazar CEO & Founder | Top 10M | — | 1 launch |
| 41 | Omrix Biopharmaceuticals Developer of biopharmaceutical products derived from human plasma | $2M | 256 mo ago | Acquired | — | — | — | 652 patents Oxidized cellulose-based hemostatic and anti‑adhesion biomaterials for surgical wound care | — |
| 42 | Paieon Imaging analysis solutions for cardio-vascular interventional procedures | $2M | 198 mo ago | Deadpooled | 28 | Ron Davidson CEO | — | 21 patents Cardiac device navigation and lead placement with real-time heart mechanics analysis. | — |
| 43 | BioLert Smartwatch wearable for the detection of epilepsy seizures | $2M | 174 mo ago | Funding Raised | — | Avi Yaron CEO | — | 7 patents Wearable medical devices for real-time epileptic seizure detection and monitoring. | — |
| 44 | Thrombotech Peptide drug for the treatment of ischemic stroke | $1M | 171 mo ago | Acqui-Hired | — | Ruth Yakar CEO | — | 22 patents Therapeutic peptides modulating plasminogen activators for cardiovascular and hypertension treatment | — |
| 45 | MEway Pharma Pulmonary drug delivery devices | $1M | 137 mo ago | Deadpooled | — | Eran Eilat Co-Founder | — | 13 patents Inhalation drug delivery devices: nebulizers and metered‑dose inhalers for respiratory therapy. | — |
| 46 | Pylon Medical Manufacturer of medical devices specializing in carotid stenting | $1M | 22 mo ago | Seed | — | Or Zigelboim Founder & CEO | — | — | — |
| 47 | Amorphical Amorphous calcium carbonate for osteoporosis & other calcium-related diseases | $1M | 147 mo ago | Seed | 15 | Yossi Ben Founder & CEO | Top 50M | 218 patents Pharmaceutical and nutraceutical formulations of amorphous calcium carbonate for therapeutic uses | 2 job openings |
| 48 | Phenome Networks Developer of software for plant breeding and variety testing processes | $510K | 68 mo ago | Series A | 25 | — | Top 5M | — | — |
| 49 | MataGene Biotechnology company offering technology to enhance crop photosynthesis using genetic engineering | $250K | 46 mo ago | Seed | — | Vivekanand Tiwari Co-Founder | — | — | — |
| 50 | TavTech Jet technology for aesthetic & medical applications | $200K | 309 mo ago | Early Stage | 21 | Izhak Yaniv CEO | Top 50M | 33 patents High‑velocity jet spray devices for transdermal drug and skin‑treatment delivery | 4 launchs |
Top 12 Life Sciences companies in Center District
#1
Public · Ness Ziona, Center District · founded 2015 · 65 employees$56Mraised▾
Public · Ness Ziona, Center District · founded 2015 · 65 employees
Microbiome therapeutics for diseases associated with microbiome dysbiosis. The company offers its flagship 3-tier microbiome modulation platform which is an end-to-end platform to identify target bacteria causing microbiome dysbiosis, modulate the microbiome through adding or eradicating bacteria. It also has a GI tract cancer program in prototype discovery and a checkpoint inhibitor program in target discovery.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 20%Patents
top 34%Growth
top 37%Tech
top 37%Moat
top 38%Innovation
top 45%Funding: Raised $56.0M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) · Last round Post IPO (Jan 2026)
Patents: 42 patents matched (strict assignee match) · 24 filings since 2022 vs 18 in 2017-21 · Latest publication 2025
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Audience (LinkedIn): 9k LinkedIn followers — 5.3% of this cohort's audience
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Jan 2026Post IPO$3.3M
- Feb 2025Post IPO$12M
- Mar 2024Post IPO$50M
- Mar 2023Post IPO$1.5M
Investors
Orbimed, Johnson & Johnson Innovation – JJDC, Takeda Ventures, 8VC, Seventure Partners, SBI JI
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#2
Public · Ness Ziona, Center District · founded 2004 · 73 employees$16.3Mraised▾
Public · Ness Ziona, Center District · founded 2004 · 73 employees
Developer of recombinant human collagen for regenerative medicine and aesthetics. It focuses on creating technologies and products for tissue regeneration and organ manufacturing. The company's plant-based technology enables the production of recombinant human type I collagen. This collagen is identical to that produced by the human body. The company develops products aimed at bioprinting tissues and organs and medical aesthetics.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 22%Funding
top 26%Product
top 26%Tech
top 35%Moat
top 35%Innovation
top 43%Patents: 170 patents matched (strict assignee match) · 41 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Funding: Raised $16.3M across 11 rounds · 11 rounds over 20 yrs (0.6/yr) · Last round Post IPO (Feb 2026)
Product: 1 product launch event in 12 mo · Company stage: Public
Funding rounds
- Feb 2026Post IPO$4M
- Feb 2020Post IPO$4.5M
- Sep 2019Post IPO$5.5M
- Nov 2017Post IPO$2M
Investors
Invesco, Alpha Capital Partners, Docor, Pontifax, Rocky Point Ventures
Tech stack
Apache Http ServerBootstrapCloudflareCloudflare Bot ManagementComplianzContact Form 7
#3
Series D · Kadima Zoran, Center District · founded 2012 · 63 employees$183Mraised▾
Series D · Kadima Zoran, Center District · founded 2012 · 63 employees
Magenta Medical is focussed on developing a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF). It is developing its device for renal venous congestion and its deleterious effects on renal and cardiac function.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Patents
top 17%Innovation
top 21%Funding
top 26%Moat
top 28%Product
top 31%Market
top 45%Patents: 440 patents matched (strict assignee match) · 291 filings since 2022 vs 129 in 2017-21 · Latest publication 2026
Innovation: 440 patents (top 6% of patent-holders) · 291 filings since 2022 vs 129 in 2017-21 · 2 product lines
Funding: Raised $183M across 4 rounds · 4 rounds over 14 yrs (0.3/yr) · Last round Series D (Jul 2024)
Audience (LinkedIn): 14k LinkedIn followers — 8.9% of this cohort's audience
Funding rounds
- Jul 2024Series D$105M
- May 2023Series C$55M
- Jul 2019Series B—
- Sep 2017Series B$15M
Investors
Orbimed, New Enterprise Associates, Pitango, ALIVE, Novo Holdings, Viking Global Investors
Tech stack
WordpressMysqlPhpBootstrapWp RocketElementor
#4
Series B · Ness Ziona, Center District · founded 2017 · 17 employees$41.8Mraised▾
Series B · Ness Ziona, Center District · founded 2017 · 17 employees
Developer of transcatheter solutions for patients with heart diseases. The company's percutaneous device Trillium is designed to provide treatment of tricuspid regurgitation.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 31%Moat
top 32%Innovation
top 41%Patents
top 42%Talent
bottom 49%Global
bottom 43%Funding: Raised $41.8M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Oct 2024)
Moat: Editorial + unicorn rating 4/10 · IP moat: 37 patents
Innovation: 37 patents (top 55% of patent-holders) · 22 filings since 2022 vs 15 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Oct 2024Series B$28.5M
- Jun 2022Grant (prize money)$2.7M
- Nov 2021Grant (prize money)$2.9M
- Nov 2021Series A$13.3M
Founders & team
Investors
EIC Fund, RA Capital Management, BRM, JG Investment, Europa, Mivtach Shamir Holdings
#5
Series A · Ness Ziona, Center District · founded 2018 · 7 employees$8Mraised▾
Series A · Ness Ziona, Center District · founded 2018 · 7 employees
Developer of therapies for rare dermatologic diseases and itch conditions. It offers topical and oral TRPV3 inhibitors treatment of Lichen simplex chronicus related itch, Palmoplantar Keratoderma, and Ichthyosis.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Moat
top 32%Patents
top 36%Innovation
top 42%Funding
top 46%Global
bottom 40%Market
bottom 23%Moat: Editorial + unicorn rating 4/10 · IP moat: 28 patents
Patents: 28 patents matched (strict assignee match) · 26 filings since 2022 vs 2 in 2017-21 · Latest publication 2025
Innovation: 28 patents (top 61% of patent-holders) · 26 filings since 2022 vs 2 in 2017-21
Funding rounds
- Jun 2025Series A$23M
- Sep 2022Series A$8M
Investors
GIBF, BRM, Pontifax, Wille Finance
#6
Public · Yavne, Center District · founded 2001 · 83 employees$18Mraised▾
Public · Yavne, Center District · founded 2001 · 83 employees
Developer of enzymatic therapeutic solutions for tissue repair and regeneration. It leverages enzymatic technology to develop active therapies for burn, wound care, and biological medicinal products for tissue repair. The product portfolio includes NexoBrid, EscharEx, and MW005, topical enzymatic therapy for the treatment of non-melanoma skin cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Talent
top 33%Funding
top 34%Patents
top 36%Global
top 39%Innovation
top 43%News
top 43%Talent: 3 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $18.0M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) · Last round Grant (prize money) (Jul 2024)
Patents: 111 patents matched (strict assignee match) · 24 filings since 2022 vs 38 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 7k LinkedIn followers — 4.6% of this cohort's audience
Funding rounds
- Jul 2024Grant (prize money)$17.7M
- Dec 2023Grant (prize money)$6.7M
- Feb 2023Post IPO$27.5M
- Sep 2022Post IPO$30M
Founders & team
Investors
Point72, Deep Insight, Israel Biotech Fund, aMoon, Clal Biotechnology Industries, MTEC
Tech stack
Amazon SesAmazon Web ServicesCloudflareCloudflare Browser InsightsContact Form 7Core-Js
#7
Series C · Ness Ziona, Center District · founded 2000 · 16 employees$14.9Mraised▾
Series C · Ness Ziona, Center District · founded 2000 · 16 employees
NanoPass Technologies develops intradermal delivery solutions for vaccines and immunotherapies. They have developed, MicronJet needle, a single use microneedles-based device for intradermal delivery. It can be used with any standard syringe to painlessly deliver any liquid substance directly into the skin. The MicronJet can be used with any standard syringe to inject drugs, proteins and vaccines approved for that delivery route.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Innovation
top 39%Patents
top 39%Funding
top 42%Moat
top 45%Tech
top 48%Talent
bottom 49%Innovation: 75 patents (top 36% of patent-holders)
Patents: 75 patents matched (strict assignee match) · Latest publication 2016 · 3 distinct CPC technology classes
Funding: Raised $14.9M across 2 rounds · 2 rounds over 19 yrs (0.1/yr) · Last round Series C (Jul 2024)
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 3 product launches · 1 partnerships (incl. IMD Ltd) announced in 12 mo
Funding rounds
- Jul 2024Series C$6M
- Apr 2016Series C—
- Jul 2012Series B—
- Feb 2007Series A$6.5M
Founders & team
Investors
Israel HealthCare Ventures, XT Hi-Tech, West Pharmaceutical Services, WFD Ventures, D Capital Partners, Awz Ventures
Tech stack
Apache Http ServerBootstrapCloudflareCloudflare Browser InsightsComplianzFlexslider
#8
Series B · Modi in Maccabim Re ut, Center District · founded 2011 · 25 employees$14.7Mraised▾
Series B · Modi in Maccabim Re ut, Center District · founded 2011 · 25 employees
Developer of nitinol based contraceptive devices for womens health, It develops intrauterine devices (IUD) made from Nitinol for contraception & IUB copper pearls consist of a special shape memory alloy. Once the flexible IUB frame is released from the insertion tube in the uterus. It offers IUB BALLERINE hormone-free smart IUD, IUB SEAD a endometrial ablation device, and IUB PRIMA for therapeutic-delivery to target therapy areas such as endometriosis and myomas.
Funding rounds
- Jun 2024Grant (prize money)—
- Jun 2024Series B$10M
- Dec 2020Series A—
- Oct 2017Series A—
Founders & team
Investors
Chemo, Rhia Ventures, RH Capital, EXERTE, Astia, Features Capital
Tech stack
WordpressMysqlPhpHello ElementorElementorYoast Seo
#9
Vayyar 🦄Series E · Yehud, Center District · founded 2011 · 330 employees$296Mraised▾
Vayyar 🦄
Series E · Yehud, Center District · founded 2011 · 330 employees
Developer of 4D imaging sensors for cancer detection and other devices. It offers a hand-held screening device that generates high-resolution 3D images that detect breast cancer by using radio frequency technology. Also, it develops touchless fall detection for seniors. It provides various products for multiple industries such as retail, public safety, robotics, and smart buildings.
Funding rounds
- Jun 2022Series E$108M
- Nov 2019Series D$109M
- Dec 2017Series C$45M
- Dec 2015Series B$22M
Founders & team
Investors
Koch Disruptive Technologies, Battery Ventures, Bessemer Venture Partners, MoreVC, Claltech, GLy Capital
Tech stack
AstraBootstrapCdnjsCloudflareCloudflare Bot ManagementCloudflare Browser Insights
#10
Acquired · Kokhav Ya ir Tzur Yigal, Center District · founded 2001 · 1 employees$46.1Mraised▾
Acquired · Kokhav Ya ir Tzur Yigal, Center District · founded 2001 · 1 employees
BioProtect is developing radiation protection technology. The company has developed a BioProtect/ ProSpace Balloon System which acts as a spacer and pushes healthy tissue away from the high-dose radiation field for patients receiving radiotherapy for prostate cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 4.4% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Oct 2023Grant (prize money)$2.6M
- Sep 2020Series D$25M
- Jan 2020Series D$13M
- Apr 2017Series A$3.5M
Founders & team
Investors
Peregrine Ventures, KB Investment, Almeda Ventures, Triventures, Medtronic, Accelmed Ventures
Tech stack
WordpressMysqlPhpBootstrapContact Form 7Yoast Seo
#11
Acquired · Rosh Haayin, Center District · founded 2014 · 13 employees$62.5Mraised▾
Acquired · Rosh Haayin, Center District · founded 2014 · 13 employees
Developer of denervation catheter for the treatment of pulmonary hypertension. It has developed a therapeutic catheter called TIVUS (Therapeutic Intra-Vascular Ultrasound) which can be inserted into the pulmonary artery and then selectively damages nerves associated with disease activity without touching the vessel walls or damaging the adjacent tissues.
Funding rounds
- Jan 2023Series C$60M
- Nov 2015Series A$2.5M
Founders & team
Investors
Andera Partners, Supernova Invest, Omega Funds, TechWald Holding, Accelmed, Arkin Holdings
#12
Seed · Ness Ziona, Center District · founded 2023$1.2Mraised▾
Seed · Ness Ziona, Center District · founded 2023
Manufacturer of medical devices specializing in carotid stenting. The company's product is a percutaneous transcarotid stenting system to provide a safer method for carotid artery access, which aims to reduce complications associated with traditional approaches.
Funding rounds
- Jul 2024Seed$1.2M
Founders & team
Investors
MEDX Xelerator
Funding & investor landscape
$1.5Btotal disclosed funding
52companies funded
132disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Rafi Benary
Founder · Innoventric
Lior Rosenberg
Founder & Cmo · MediWound
Ofer Gonen
· MediWound
Daniel Levitats
Chief Executive Officer · NanoPass Technologies
Ilan Baram
Founder · OCON Medical
Raviv Melamed
Co-Founder & CEO · Vayyar
Miri Ratner
VP R&D and Co-Founder · Vayyar
Shaul Shohat
Co-Founder & CTO · BioProtect
Adrian Paz
Co-Founder · BioProtect
Tomaso Zambelli
CEO · SoniVie
Or Zigelboim
Founder & CEO · Pylon Medical
Uri Rapport
Founder & CEO · Aspect Imaging
Prism market signals · Israel · country-scoped Prism corpus, 1,211,671 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Israel
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
top research entities
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
leading researchers
Itamar Willner · Dombrovsky, A. · Wei Zhao · Goor Sasson · Roy Novoselsky · Shalev Itzkovitz · Xiaoqing Liu · Hengyou Zhang
▲
Breakthroughs69 · 26%
▲ 0%→25% share
0 median citations80% since 2021mostly empirical
Gene research newly emerged with 10 papers, alongside Transcription factor and Mutant, driving Breakthroughs from 0% to 25% field-share.
rising sub-themes (early→recent)
- Mitochondrion1→5
Newly emergingGene 0→10 · Transcription factor 0→5 · Mutant 0→5
Landmark The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity · 3,514 cites
◆
Advancements119 · 45%
▲ 0%→48% share
0 median citations90% since 2021mostly empirical
Gene studies surged 1→18 papers; Transcriptome and Microbiome newly emerged, pushing Advancements to 48% field-share.
rising sub-themes (early→recent)
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
Newly emergingTranscriptome 0→8 · Microbiome 0→8 · Selection (genetic algorithm) 0→7
Landmark Plant Growth-Promoting Rhizobacteria: Context, Mechanisms of Action, and Roadmap to Commercialization of Biostimulants f · 1,849 cites
▼
Concerns43 · 16%
▲ 0%→14% share
0 median citations74% since 2021mostly reviews
Agriculture concern papers doubled 3→6, intensifying as Concerns grew from 0% to 14% field-share.
rising sub-themes (early→recent)
- Agriculture3→6
Landmark Genetic Engineering for Modern Agriculture: Challenges and Perspectives · 1,148 cites
RESEARCH HOTSPOTS · Israel
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Jerusalem29 · +0.39
Tel Aviv27 · +0.41
Beer Sheva19 · +0.60
Haifa17 · +0.40
Rehovot16 · +0.53
Common questions
How many Life Sciences companies are there in Center District, Israel?
Radar tracks 163 indexable Life Sciences companies headquartered in Center District, Israel that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Center District, Israel?
The Life Sciences companies in Center District, Israel on this list have raised a combined $1.5B in disclosed equity funding across 52 funded companies.
Which is the highest-funded Life Sciences company in Center District, Israel?
Vayyar is the highest-funded Life Sciences company in Center District, Israel, with $296M in disclosed equity funding.
How many Life Sciences companies in Center District, Israel are funded?
52 of the 163 Life Sciences companies in Center District, Israel on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Center District, Israel?
1 Life Sciences company in Center District, Israel on this list is valued at $1B or more.
Who are the top investors in Center District, Israel Life Sciences companies?
The most active investors in Center District, Israel Life Sciences companies on this list include Europa, Pontifax, EIC Fund, Sanara Ventures, Arkin Holdings.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.